$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

$acad Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024021473 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$205.8M	$231.0M	$726.4M
YoY Change	73.75%	69.27%	40.45%
Cost Of Revenue	$22.95M	$17.89M	$41.64M
YoY Change	1276.78%	641.44%	309.58%
Gross Profit	$182.9M	$213.2M	$684.8M
YoY Change	56.58%	58.98%	35.05%
Gross Profit Margin	88.85%	92.26%	94.27%
Selling, General & Admin	$108.0M	$111.5M	$406.6M
YoY Change	6.67%	6.77%	10.15%
% of Gross Profit	59.05%	52.29%	59.37%
Research & Development	$59.68M	$66.74M	$351.6M
YoY Change	-13.69%	-11.88%	-2.75%
% of Gross Profit	32.63%	31.31%	51.35%
Depreciation & Amortization	$242.0K	$1.637M	$1.500M
YoY Change	-43.19%	234.76%	-25.0%
% of Gross Profit	0.13%	0.77%	0.22%
Operating Expenses	$167.7M	$178.2M	$758.2M
YoY Change	-1.59%	-1.07%	3.77%
Operating Profit	$15.21M	$34.95M	-$73.38M
YoY Change	-128.39%	-175.86%	-67.18%
Interest Expense	$5.506M	$4.759M	$17.23M
YoY Change	44.89%	31.1%	160.73%
% of Operating Profit	36.2%	13.62%
Other Income/Expense, Net	$286.0K	$0.00	$5.109M
YoY Change	-94.1%	-100.0%	44.24%
Pretax Income	$21.00M	$39.70M	-$51.04M
YoY Change	-146.77%	-197.1%	-76.09%
Income Tax	$4.400M	-$6.094M	$10.25M
% Of Pretax Income	20.95%	-15.35%
Net Earnings	$16.56M	$45.80M	-$61.29M
YoY Change	-138.48%	-209.76%	-71.62%
Net Earnings / Revenue	8.04%	19.82%	-8.44%
Basic Earnings Per Share	$0.10	$0.28	-$0.37
Diluted Earnings Per Share	$0.10	$0.28	-$0.37
COMMON SHARES
Basic Shares Outstanding	164.8M	164.2M	163.8K
Diluted Shares Outstanding	166.6M		163.8K

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$470.5M	$438.9M	$438.9M
YoY Change	16.79%	5.29%	5.29%
Cash & Equivalents	$204.7M	$188.7M	$188.7M
Short-Term Investments	$265.8M	$250.2M	$250.2M
Other Short-Term Assets	$42.76M	$39.09M	$39.09M
YoY Change	80.95%	82.69%	82.69%
Inventory	$66.64M	$40.45M	$35.82M
Prepaid Expenses	$42.76M	$39.09M
Receivables	$94.70M	$98.27M	$98.27M
Other Receivables	$5.378M	$4.083M	$4.083M
Total Short-Term Assets	$675.3M	$616.1M	$616.1M
YoY Change	34.29%	21.3%	21.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.370M	$4.612M	$56.47M
YoY Change	-21.89%	-23.4%	-8.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$476.0K	$476.0K	$10.87M
YoY Change	-96.17%	-93.73%	-40.52%
Total Long-Term Assets	$179.8M	$132.8M	$132.8M
YoY Change	17.94%	66.3%	66.3%
TOTAL ASSETS
Total Short-Term Assets	$675.3M	$616.1M	$616.1M
Total Long-Term Assets	$179.8M	$132.8M	$132.8M
Total Assets	$855.1M	$749.0M	$749.0M
YoY Change	30.49%	27.41%	27.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.33M	$17.54M	$17.54M
YoY Change	10.96%	37.64%	37.64%
Accrued Expenses	$311.3M	$236.7M	$236.7M
YoY Change	50.46%	109.69%	109.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$330.6M	$254.3M	$254.3M
YoY Change	47.39%	102.38%	102.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$11.27M	$15.15M	$62.95M
YoY Change	112.5%	66.93%	1.91%
Total Long-Term Liabilities	$11.27M	$15.15M	$62.95M
YoY Change	112.5%	66.93%	1.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$330.6M	$254.3M	$254.3M
Total Long-Term Liabilities	$11.27M	$15.15M	$62.95M
Total Liabilities	$391.1M	$317.2M	$317.2M
YoY Change	39.14%	69.27%	69.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.414B	-$2.431B
YoY Change	0.07%	2.59%
Common Stock	$2.879B	$2.863B
YoY Change	3.28%	3.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$464.0M	$431.8M	$431.8M
YoY Change
Total Liabilities & Shareholders Equity	$855.1M	$749.0M	$749.0M
YoY Change	30.49%	27.41%	27.41%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$16.56M	$45.80M	-$61.29M
YoY Change	-138.48%	-209.76%	-71.62%
Depreciation, Depletion And Amortization	$242.0K	$1.637M	$1.500M
YoY Change	-43.19%	234.76%	-25.0%
Cash From Operating Activities	$29.08M	$85.39M	$16.70M
YoY Change	-262.15%	-457.97%	-114.65%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$50.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$14.04M	-$347.0K	$72.05M
YoY Change	-107.29%	-98.04%	-1.63%
Cash From Investing Activities	-$14.04M	-$347.0K	$32.00M
YoY Change	-107.29%	-98.04%	-56.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$25.13M
YoY Change			206.49%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.043M	5.434M	25.13M
YoY Change	-28.85%	236.68%	206.49%
NET CHANGE
Cash From Operating Activities	29.08M	85.39M	16.70M
Cash From Investing Activities	-14.04M	-347.0K	32.00M
Cash From Financing Activities	1.043M	5.434M	25.13M
Net Change In Cash	16.09M	90.48M	73.81M
YoY Change	-90.86%	-326.26%	-326.49%
FREE CASH FLOW
Cash From Operating Activities	$29.08M	$85.39M	$16.70M
Capital Expenditures		$0.00	$50.00K
Free Cash Flow		$85.39M	$16.65M
YoY Change		-457.97%	-114.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001070494
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-50768
CY2023	dei	Entity Registrant Name EntityRegistrantName	ACADIA PHARMACEUTICALS INC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1376651
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	12830 El Camino Real
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2023	dei	City Area Code CityAreaCode	858
CY2023	dei	Local Phone Number LocalPhoneNumber	558-2871
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	ACAD
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2900000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	164771521
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	California
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	188657000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114846000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	250208000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	301977000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	98267000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62195000
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	4083000
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	885000
CY2023Q4	acad	Short Term Inventory ShortTermInventory	35819000
CY2022Q4	acad	Short Term Inventory ShortTermInventory	6636000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	39091000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	21398000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	616125000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	507937000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4612000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6021000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	51855000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	55573000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	65490000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2023Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	4628000
CY2022Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	4924000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	476000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7587000
CY2023Q4	us-gaap	Assets Assets	748956000
CY2022Q4	us-gaap	Assets Assets	587812000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17543000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12746000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	236711000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	112884000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	254254000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	125630000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47800000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52695000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15147000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9074000
CY2023Q4	us-gaap	Liabilities Liabilities	317201000
CY2022Q4	us-gaap	Liabilities Liabilities	187399000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	164650219
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	164650219
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	162064872
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	162064872
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2862552000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2770923000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2430837000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2369551000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-975000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	431755000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	400413000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	748956000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	587812000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	726437000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	517235000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	484145000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	726437000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	517235000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	484145000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	41638000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10166000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19141000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	351619000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	361575000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	239415000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	406559000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	369090000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	396028000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	799816000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	740831000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	654584000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-73379000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-223596000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-170439000
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	17234000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6610000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	591000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5109000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3542000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2329000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51036000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-213444000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-167519000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10250000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2531000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	351000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61286000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-215975000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	163819
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	163819
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	161683
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	161683
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160493
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	160493
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61286000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-215975000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1017000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-789000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-235000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-18000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60287000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-216758000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-168098000
CY2023	us-gaap	Profit Loss ProfitLoss	-61286000
CY2022	us-gaap	Profit Loss ProfitLoss	-215975000
CY2021	us-gaap	Profit Loss ProfitLoss	-167870000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	66421000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	68201000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	63615000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	7533000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2736000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2404000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4093000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1108000
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	5109000
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	3542000
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	2329000
CY2023	us-gaap	Depreciation Depreciation	1459000
CY2022	us-gaap	Depreciation Depreciation	2026000
CY2021	us-gaap	Depreciation Depreciation	2236000
CY2023	acad	Loss On Sale Of Investment Securitie LossOnSaleOfInvestmentSecuritie	524000
CY2022	acad	Loss On Sale Of Investment Securitie LossOnSaleOfInvestmentSecuritie	0
CY2021	acad	Loss On Sale Of Investment Securitie LossOnSaleOfInvestmentSecuritie	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	36072000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2171000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16119000
CY2023	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	3198000
CY2022	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-93000
CY2021	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-1057000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28808000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2415000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4210000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17693000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2494000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1802000
CY2023	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-5769000
CY2022	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-6566000
CY2021	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-6287000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	33000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	48000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-10000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4797000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5870000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1617000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	93170000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	24306000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8455000
CY2023	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5872000
CY2022	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-7916000
CY2021	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5433000
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	6073000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2040000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1854000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	16702000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-114035000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-125660000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	369985000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	363174000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	492797000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	429780000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	436415000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	422817000
CY2023	acad	Proceeds From Sales Of Strategic Investment ProceedsFromSalesOfStrategicInvestment	12253000
CY2022	acad	Proceeds From Sales Of Strategic Investment ProceedsFromSalesOfStrategicInvestment	0
CY2021	acad	Proceeds From Sales Of Strategic Investment ProceedsFromSalesOfStrategicInvestment	0
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1122000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	40000000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	31998000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	73241000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71102000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25129000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8199000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18162000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25129000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8199000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18162000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-18000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	73811000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32589000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-178593000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120616000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194427000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120616000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5850000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2190000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1038000
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	29583000
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627009000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12850000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5312000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63821000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-228000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	540894000
CY2022	acad	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	3705000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4494000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-215975000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	68078000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-783000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	400413000
CY2023	acad	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	20309000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4820000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61286000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	66500000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	999000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	431755000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114846000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	188657000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147435000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114846000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120616000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194427000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120616000
CY2023Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0
CY2022Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	900000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	600000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	1300000
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2023	us-gaap	Advertising Expense AdvertisingExpense	9400000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	5500000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	41800000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	726437000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	517235000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	484145000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, investment securities, accounts receivable, and restricted cash. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations and government sponsored enterprises in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. All investment securities have a credit rating of at least Aa3/AA- or better, or P-1/A-1 or better, as determined by Moody’s Investors Service or Standard & Poor’s. Further, the Company specifies credit quality standards for its customers that are designed to limit the Company’s credit exposure to any single party.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not currently have any of its own manufacturing facilities, and therefore it depends on an outsourced manufacturing strategy for the production of NUPLAZID and DAYBUE for commercial use and for the production of its product candidates for clinical trials. For the production of NUPLAZID, the Company has contracts in place with two third-party manufacturers of commercial drug product and one third-party manufacturer of drug substance that is approved for the production of NUPLAZID API. For the production of DAYBUE, the Company has contracts in place with two third-party manufacturers of commercial drug product and two third-party manufacturers of drug substance that is approved for the production of DAYBUE API. Although there are potential sources of supply other than the Company’s existing suppliers, any new supplier would be required to qualify under applicable regulatory requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into agreements for the distribution of NUPLAZID with a limited number of SPs and SDs, and all of the Company’s product sales of NUPLAZID are to these customers. The Company has also entered into agreements for the distribution of DAYBUE with a single wholesale distributor, and all of the Company’s product sales of DAYBUE and accounts receivable balance at December 31, 2023 are related to this customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company’s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> largest customers, including the single wholesale distributor, represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the Company’s product revenue </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the Company’s accounts receivable balance at December 31, 2023. For the year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company’s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> largest customers represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company’s product revenue and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the Company’s accounts receivable balance at December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2023	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2022	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2023	acad	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Forfeited FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseForfeited	-128000
CY2021	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	6800000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66421000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	68201000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63615000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21264000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21185000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17535000
CY2023Q4	acad	Debt Securities And Equity Securities Fv Ni Amortized Cost DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	250182000
CY2023Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Gains DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	166000
CY2023Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Losses DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	140000
CY2023Q4	acad	Debt Securities And Equity Securities Fv Ni DebtSecuritiesAndEquitySecuritiesFvNi	250208000
CY2022Q4	acad	Debt Securities And Equity Securities Fv Ni Amortized Cost DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	302968000
CY2022Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Gains DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	46000
CY2022Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Losses DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	1037000
CY2022Q4	acad	Debt Securities And Equity Securities Fv Ni DebtSecuritiesAndEquitySecuritiesFvNi	301977000
CY2023	acad	Available For Sale Investment Securities Contractual Maturity Dates AvailableForSaleInvestmentSecuritiesContractualMaturityDates	less than one year
CY2022	acad	Available For Sale Investment Securities Contractual Maturity Dates AvailableForSaleInvestmentSecuritiesContractualMaturityDates	less than one year
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	21
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	43
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	149953000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	140000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	149953000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	140000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	230174000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1037000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	230174000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1037000
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	183000000
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	500000
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	314794000
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	4506000
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	395597000
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	898000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	898000
CY2023	acad	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Vesting Of Awards FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityVestingOfAwards	772000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	2964000
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4506000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5001000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1926000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4134000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4427000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	31312000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5207000
CY2023Q4	us-gaap	Inventory Net InventoryNet	40447000
CY2022Q4	us-gaap	Inventory Net InventoryNet	11560000
CY2023Q4	acad	Short Term Inventory ShortTermInventory	35819000
CY2022Q4	acad	Short Term Inventory ShortTermInventory	6636000
CY2023Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	4628000
CY2022Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	4924000
CY2023Q4	us-gaap	Inventory Net InventoryNet	40447000
CY2022Q4	us-gaap	Inventory Net InventoryNet	11560000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14168000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14118000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9556000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8097000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4612000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6021000
CY2023	us-gaap	Depreciation Depreciation	1500000
CY2022	us-gaap	Depreciation Depreciation	2000000
CY2021	us-gaap	Depreciation Depreciation	2200000
CY2023	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0
CY2022	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	100000
CY2023Q4	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	90718000
CY2022Q4	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	26046000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	42718000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	28023000
CY2023Q4	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	32883000
CY2022Q4	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	35048000
CY2023Q4	acad	Accrued Contingent Payments AccruedContingentPayments	29583000
CY2022Q4	acad	Accrued Contingent Payments AccruedContingentPayments	0
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	18804000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	11377000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9405000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9305000
CY2023Q4	acad	Accrued Taxes AccruedTaxes	1564000
CY2022Q4	acad	Accrued Taxes AccruedTaxes	377000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11036000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2708000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	236711000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	112884000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16339465
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.83
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3157634
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.99
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1046035
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	19.42
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1825035
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	32.07
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16626029
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.75
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	90962000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	11152607
CY2023Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice	31.12
CY2023	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm1	P4Y2M12D
CY2023Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue1	44951000
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	5473422
CY2023Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageExercisePrice	23.92
CY2023	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2023Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue1	46012000
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	31.31
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7900000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8000000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20300000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3700000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12900000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.66
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.07
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	62100000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	63900000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	66000000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	PSUs for which the number of shares issuable at the end of performance period can reach up to 200% of the shares approved in the award based on the achievement of certain pre-defined Acadia-specific performance criteria and continued employment through the vesting period
CY2021Q4	us-gaap	Deferred Compensation Arrangement With Individual Cash Award Granted Amount DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount	15100000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	4400000
CY2023Q4	us-gaap	Deferred Compensation Arrangement With Individual Cash Award Granted Amount DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount	10100000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	5200000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	1800000
CY2023	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	4500000
CY2022	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	900000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	3600000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	300000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	10250000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2531000
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	6100000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	5100000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	5800000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-100215000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-233216000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-138913000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	49179000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	19772000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-28606000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-51036000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-213444000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-167519000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	5440000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4805000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2531000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	351000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	5000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	351000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10250000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2531000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	351000
CY2023Q4	acad	Federal Research And Development Credit Carryforwards FederalResearchAndDevelopmentCreditCarryforwards	75600000
CY2023Q4	acad	State Research And Development Credit Carryforwards StateResearchAndDevelopmentCreditCarryforwards	2300000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	149049000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	225993000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	70906000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	83074000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	90164000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	38507000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	51028000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	51661000
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	40956000
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	42677000
CY2023Q4	acad	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	13671000
CY2022Q4	acad	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	14730000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	43220000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	24030000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	51000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0
CY2023Q4	acad	Deferred Tax Asset Accrued Rebates DeferredTaxAssetAccruedRebates	19401000
CY2022Q4	acad	Deferred Tax Asset Accrued Rebates DeferredTaxAssetAccruedRebates	5748000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16036000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	8022000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	494482000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	494442000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	482089000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	481210000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	29000
CY2023Q4	acad	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	12393000
CY2022Q4	acad	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	13203000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12393000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	13232000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	900000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10718000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-44823000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-35179000
CY2023	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	8458000
CY2022	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	7596000
CY2021	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	6083000
CY2023	acad	Income Tax Expense Branded Pharmaceutical Drug Fee IncomeTaxExpenseBrandedPharmaceuticalDrugFee	1848000
CY2022	acad	Income Tax Expense Branded Pharmaceutical Drug Fee IncomeTaxExpenseBrandedPharmaceuticalDrugFee	1454000
CY2021	acad	Income Tax Expense Branded Pharmaceutical Drug Fee IncomeTaxExpenseBrandedPharmaceuticalDrugFee	613000
CY2023	acad	Income Tax Expenses Write Off Of Iprd IncomeTaxExpensesWriteOffOfIPRD	0
CY2022	acad	Income Tax Expenses Write Off Of Iprd IncomeTaxExpensesWriteOffOfIPRD	2449000
CY2021	acad	Income Tax Expenses Write Off Of Iprd IncomeTaxExpensesWriteOffOfIPRD	1277000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-5827000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-9974000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-11727000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1100000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11227000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	36099000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-977000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2232000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2617000
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-2071000
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	6993000
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	3879000
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-5076000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1971000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2857000
CY2023	acad	Income Tax Reconciliation Limitation On Executive Compensation IncomeTaxReconciliationLimitationOnExecutiveCompensation	2112000
CY2022	acad	Income Tax Reconciliation Limitation On Executive Compensation IncomeTaxReconciliationLimitationOnExecutiveCompensation	3918000
CY2021	acad	Income Tax Reconciliation Limitation On Executive Compensation IncomeTaxReconciliationLimitationOnExecutiveCompensation	1808000
CY2023	acad	Income Tax Reconciliation Deferred Rate Adjustment IncomeTaxReconciliationDeferredRateAdjustment	-192000
CY2022	acad	Income Tax Reconciliation Deferred Rate Adjustment IncomeTaxReconciliationDeferredRateAdjustment	922000
CY2021	acad	Income Tax Reconciliation Deferred Rate Adjustment IncomeTaxReconciliationDeferredRateAdjustment	-2424000
CY2023	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	-246000
CY2022	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	0
CY2021	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	-923000
CY2023	acad	Effective Income Tax Rate Reconciliation Expiration Of Attributes Amount EffectiveIncomeTaxRateReconciliationExpirationOfAttributesAmount	17225000
CY2022	acad	Effective Income Tax Rate Reconciliation Expiration Of Attributes Amount EffectiveIncomeTaxRateReconciliationExpirationOfAttributesAmount	16142000
CY2021	acad	Effective Income Tax Rate Reconciliation Expiration Of Attributes Amount EffectiveIncomeTaxRateReconciliationExpirationOfAttributesAmount	726000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	7665000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	10804000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	0
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-3051000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	26000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-121000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10250000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2531000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	351000
CY2023	acad	Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions	18000000
CY2022	acad	Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions	5100000
CY2021	us-gaap	Sublease Income SubleaseIncome	-0
CY2023	us-gaap	Lease Cost LeaseCost	10250000
CY2022	us-gaap	Lease Cost LeaseCost	8095000
CY2021	us-gaap	Lease Cost LeaseCost	8874000
CY2021	acad	Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions	4100000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6800000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1200000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	19064000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13923000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9843000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5304000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5140000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3973000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	12956000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	38000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	140000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	212000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	37000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	33000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	37112000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	19064000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13923000
CY2023	acad	Lease Expiration Month And Year LeaseExpirationMonthAndYear	2031-02
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 0.9 year to 7.4 years, some of which include options to extend the lease for up to two five-year terms.
CY2022	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	some of which include options to extend the lease for up to two five-year terms.
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	10343000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8095000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	8874000
CY2023	us-gaap	Sublease Income SubleaseIncome	93000
CY2022	us-gaap	Sublease Income SubleaseIncome	-0
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	9456000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	9083000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2051000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3871000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9405000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9305000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47800000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52695000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	57205000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62000000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9662000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9744000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9127000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8831000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8521000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	20586000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	66471000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9266000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	57205000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044
CY2020Q3	acad	Capitalization Of Lease Liability CapitalizationOfLeaseLiability	40300000
CY2021Q1	acad	Capitalization Of Lease Liability CapitalizationOfLeaseLiability	19200000
CY2023Q1	us-gaap	Revenues Revenues	118462000
CY2023Q2	us-gaap	Revenues Revenues	165235000
CY2023Q3	us-gaap	Revenues Revenues	211699000
CY2023Q4	us-gaap	Revenues Revenues	231041000
CY2023	us-gaap	Revenues Revenues	726437000
CY2023Q1	us-gaap	Gross Profit GrossProfit	116795000
CY2023Q2	us-gaap	Gross Profit GrossProfit	157776000
CY2023Q3	us-gaap	Gross Profit GrossProfit	197077000
CY2023Q4	us-gaap	Gross Profit GrossProfit	213151000
CY2023	us-gaap	Gross Profit GrossProfit	684799000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-43021000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1114000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-65176000
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	45797000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61286000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.4
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.4
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2022Q1	us-gaap	Revenues Revenues	115468000
CY2022Q2	us-gaap	Revenues Revenues	134563000
CY2022Q3	us-gaap	Revenues Revenues	130714000
CY2022Q4	us-gaap	Revenues Revenues	136490000
CY2022	us-gaap	Revenues Revenues	517235000
CY2022Q1	us-gaap	Gross Profit GrossProfit	112518000
CY2022Q2	us-gaap	Gross Profit GrossProfit	131896000
CY2022Q3	us-gaap	Gross Profit GrossProfit	128578000
CY2022Q4	us-gaap	Gross Profit GrossProfit	134076000
CY2022	us-gaap	Gross Profit GrossProfit	507068000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-113056000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-34011000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-27183000
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-41725000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-215975000
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.7
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.7
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-24-021473-index-headers.html	Edgar Link	pending
0000950170-24-021473-index.html	Edgar Link	pending
0000950170-24-021473.txt	Edgar Link	pending
0000950170-24-021473-xbrl.zip	Edgar Link	pending
acad-20231231.htm	Edgar Link	pending
acad-20231231.xsd	Edgar Link	pending
acad-ex10_13.htm	Edgar Link	pending
acad-ex10_17.htm	Edgar Link	pending
acad-ex10_18.htm	Edgar Link	pending
acad-ex10_19.htm	Edgar Link	pending
acad-ex10_20.htm	Edgar Link	pending
acad-ex10_35.htm	Edgar Link	pending
acad-ex10_36.htm	Edgar Link	pending
acad-ex10_37.htm	Edgar Link	pending
acad-ex10_38.htm	Edgar Link	pending
acad-ex10_5.htm	Edgar Link	pending
acad-ex21_1.htm	Edgar Link	pending
acad-ex23_1.htm	Edgar Link	pending
acad-ex31_1.htm	Edgar Link	pending
acad-ex31_2.htm	Edgar Link	pending
acad-ex32_1.htm	Edgar Link	pending
acad-ex32_2.htm	Edgar Link	pending
acad-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img236306118_0.jpg	Edgar Link	pending
img236306118_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
acad-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

2024 Q1 Form 10-K Financial Statement

#000095017024021473 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD ACADIA PHARMACEUTICALS INC Stock $acad

2024 Q1 Form 10-K Financial Statement

#000095017024021473 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad